Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Novartis Obtains Licenses to Develop And Commercialize Two Novel Nanobodies

Abstract:
Ablynx announced today that Novartis has obtained licenses to further develop and commercialise Nanobodies against two complex targets. This has triggered a total of 1 million in upfront fees and license payments to Ablynx.

Novartis Obtains Licenses to Develop And Commercialize Two Novel Nanobodies

Ghent, Belgium | Posted on July 14th, 2010

The two targets were the subject of programmes as part of the research agreement between the parties, entered into in 2005 and extended by mutual agreement last year. Novartis will now assume responsibility for the continued progress of both programmes and Ablynx will be eligible to receive development based milestone payments and royalties on sales following commercialisation of the products.

Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "We are excited to see these two complex programmes progressing towards the clinic in Novartis' hands and pleased that the commercial licenses have been executed. The targets are ones where conventional antibody approaches have had limited success. This is further validation of the unique nature of Ablynx's Nanobody platform, where functional Nanobodies have been successfully generated against GPCRs and ion channels. Earlier this year, we announced that we have selected a new GPCR targeting development candidate, ALX-0651, an anti-CXCR4 Nanobody which is being developed by Ablynx."

####

About Ablynx
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 240 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised 50 million through an SPO in March 2010.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development. So far, Nanobodies have been successfully generated against more than 190 different protein targets including several complex targets such as chemokines, GPCRs, ion channels and viruses, which are typically very difficult to address with conventional monoclonal antibodies. Efficacy data have been obtained in 28 in vivo models for Nanobodies against a range of different targets.
Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.

For more information, please click here

Contacts:
Ablynx nv
Technologiepark 21
9052 Ghent/Zwijnaarde
Belgium

VAT BE 0475 295 446 - RPR Gent

Tel: +32 (0)9 262 00 00
Fax: +32 (0)9 262 00 01

Copyright © Ablynx

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Graphene is strong, but is it tough? Berkeley Lab scientists find that polycrystalline graphene is not very resistant to fracture February 7th, 2016

Lithium battery catalyst found to harm key soil microorganism February 7th, 2016

Scientists take key step toward custom-made nanoscale chemical factories: Berkeley Lab researchers part of team that creates new function in tiny protein shell structures February 6th, 2016

Discovery of the specific properties of graphite-based carbon materials February 6th, 2016

Nanomedicine

Scientists take key step toward custom-made nanoscale chemical factories: Berkeley Lab researchers part of team that creates new function in tiny protein shell structures February 6th, 2016

Study reveals how herpes virus tricks the immune system February 5th, 2016

Hepatitis virus-like particles as potential cancer treatment February 5th, 2016

Researchers discover new phase of boron nitride and a new way to create pure c-BN February 5th, 2016

Announcements

Graphene is strong, but is it tough? Berkeley Lab scientists find that polycrystalline graphene is not very resistant to fracture February 7th, 2016

Lithium battery catalyst found to harm key soil microorganism February 7th, 2016

Scientists take key step toward custom-made nanoscale chemical factories: Berkeley Lab researchers part of team that creates new function in tiny protein shell structures February 6th, 2016

Discovery of the specific properties of graphite-based carbon materials February 6th, 2016

Financial Reports

Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015

Haydale Announce Year End Results November 3rd, 2015

Harris & Harris Group to Host Conference Call on Third-Quarter 2015 Financial Results on November 12, 2015 October 23rd, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

Nanobiotechnology

Scientists take key step toward custom-made nanoscale chemical factories: Berkeley Lab researchers part of team that creates new function in tiny protein shell structures February 6th, 2016

Hepatitis virus-like particles as potential cancer treatment February 5th, 2016

Novel nanoparticle made of common mineral may help keep tumor growth at bay February 4th, 2016

Nanoparticles Make Fertility Possible during Consumption of Anticancer Drugs February 4th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic